Trinity Biotech (NASDAQ:TRIB) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.

Trinity Biotech Stock Up 10.6 %

Shares of TRIB stock opened at $0.71 on Wednesday. Trinity Biotech has a twelve month low of $0.48 and a twelve month high of $3.55. The business has a fifty day simple moving average of $0.65 and a 200 day simple moving average of $0.98. The company has a market cap of $12.78 million, a P/E ratio of -0.31 and a beta of 1.21.

Hedge Funds Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC grew its position in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 378,590 shares of the company’s stock after acquiring an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the SEC. Institutional investors own 78.97% of the company’s stock.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.